VEGFA and COVID-19: A single-arm trial showed that blocking VEGF and the VEGF receptor-mediated signalling using bevacizumab, a humanized anti-VEGF monoclonal antibody, improves anti-inflammatory response and oxygen perfusion, alleviating clinical symptoms in critically ill COVID-19 patients [32].